Possible 'Best-in-Class' Alzheimer's Drug Candidate Offers 'Disruptive' Potential

Research Report
  ()
André Uddin, an analyst with Mackie Research, explained the rationale for adding this neurodegenerative disease biotech company to his firm's coverage universe. read more >

Gout, Kidney Stones, Liver Disease & Cannabinoids

Contributed Opinion
  ()
Danny Deadlock, founder of Microcap.com, profiles a company that is working on a novel drug delivery technology with a focus on cannabinoids for the potential to treat various major diseases. read more >

Biopharma Gets Green Light for Hypertension Study

Research Report
  ()
Jason McCarthy, an analyst at Maxim Group, discussed this France-based biotech firm's near-term clinical trial and catalysts. read more >

Small-Cap Biotech Benefits from First FDA Approval of CAR-T Therapy

Research Report
  ()
The first approval of a cell therapy for treatment of pediatric blood cancer prompted H. C. Wainwright to increase its price target for a UK-based biotech manufacturing one of the therapy's components. read more >

With Acquisition of Kite Pharma, Gilead Becomes a 'Major Player' in CAR-T Arena

Research Report
  ()
Jason Kolbert, analyst with Maxim Group, assesses the billion-dollar transaction that would bring Kite Pharma and the earning potential of its cell therapy programs under the larger biotech's umbrella. read more >

Analyst Says Cell Therapy Company's Move Decreases Risk

Research Report
  ()
A regenerative medicine company has signed on to the ThawSTAR Early Adopter Program, a move analyst Douglas Loe of Echelon Wealth Partners terms "positive logistically" to development risk. read more >

Medical Cannabis Innovator Set to Go Public

Initial Public Offering
  ()
A licensed producer of medical cannabis in Canada will begin trading on the Canadian Securities Exchange on Aug. 21. read more >
Expert Investing Ideas

"We continue to be optimistic about DRRX's story."

–Grant Zeng, Zacks Equity Research


Get Our Streetwise Reports Life Sciences Report Newsletter Free

A valid email address is required to subscribe
NASDAQ Biotech ARCA Pharmaceutical

Maxim Raises Target Price of Biotech Company

Research Report
  ()
A year-over-year increase in sales of its flagship product, and the prospect that its technology could be used to promote the efficacy of cell therapies, helped spur a target price increase on this biotech. read more >

Immunotherapy Company's Q2 Revenue 'Handily Beats' H.C. Wainwright's Projection

Research Report
  ()
Analyst Ram Selvaraju with H.C. Wainwright & Co. provided an update on this biotech company's REVEAL clinical programs, as well as Q2/17 earnings that exceeded expectations. read more >

'Keep a Close Eye On' This Regenerative Medicine Firm

Research Report
  ()
In an update on this company's clinical cell therapy programs targeting blood cancers and osteoarthritis in the knee, Gabrielle Zhou of Maxim Group describes progress that sets the stage for "value inflection." read more >

Over-the-Counter Treatments for Joint Pain and Women's Health Propel Company into New Markets

  ()
With the launch of its over-the-counter combination treatment for joint pain and new licensing agreements for feminine lubrication product Zestra, this San Diego-based company is expanding both its therapeutic and international reach. read more >